UNIVERSITY OF SOUTHERN CALIFORNIA
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1880-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://startusc.com
Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 35
- Registration Number
- NCT00184093
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 50
- Registration Number
- NCT00184015
- Locations
- 🇺🇸
Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
- Conditions
- Testicular CancerGerm Cell Neoplasm
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 30
- Registration Number
- NCT00183820
- Locations
- 🇺🇸
Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 15
- Registration Number
- NCT00183937
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 75
- Registration Number
- NCT00183898
- Locations
- 🇺🇸
U.S.C./Norris Comprehensive Cancer Center, Los Angeles, California, United States
Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
- Conditions
- Burkitt LymphomaNon-Hodgkin's LymphomaPrimary Effusion Lymphomas
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 15
- Registration Number
- NCT00183976
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Drug: Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 68
- Registration Number
- NCT00184002
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 11
- Registration Number
- NCT00184054
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer
- Conditions
- Recurrent Breast CancerMetastastic Breast Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 7
- Registration Number
- NCT00159458
- Locations
- 🇺🇸
Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Premiere Oncology, Santa Monica, California, United States
Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 1
- Registration Number
- NCT00159471
- Locations
- 🇺🇸
U.S.C / Norris Comprehensive Cancer Center, Los Angeles, California, United States